IN
INVLW
Innventure, Inc.
No data for this timeframe.
Vol
SEC Reports8
Recent Activity
May 14, 2026
SEC
Innventure reported Q1 2026 revenue of $1.4M, slightly below the $1.6M consensus, but the headline loss narrowed dramati
8-K — Impact 4/10
May 8, 2026
SEC
John D. Hewitt filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his holdings in Innv
3 — Impact 2/10
Apr 30, 2026
SEC
Innventure, Inc. filed a DEFA14A (definitive additional proxy soliciting materials) for its 2026 Annual Meeting of Stock
DEFA14A — Impact 2/10
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
8 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 6 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
4/10
Innventure reported Q1 2026 revenue of $1.4M, slightly below the $1.6M consensus, but the headline l
May 14, 2026
NEUTRAL
3
2/10
John D. Hewitt filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing
May 8, 2026
NEUTRAL
DEFA14A
2/10
Innventure, Inc. filed a DEFA14A (definitive additional proxy soliciting materials) for its 2026 Ann
Apr 30, 2026
BEARISH
8-K
7/10
Innventure reported full-year 2025 results with $2.056 million in revenue and a net loss of $475.35
Apr 21, 2026
BULLISH
8-K
6/10
Innventure subsidiary Accelsius announced the general availability of its NeuCool IR150 rack-level c
Apr 21, 2026
NEUTRAL
8-K
3/10
Innventure, Inc. announced an upcoming operating company CEO call on April 27, 2026, featuring execu
Apr 15, 2026
NEUTRAL
EFFECT
5/10
Innventure, Inc. has had its S-3 shelf registration become effective, allowing the company to offer
Apr 9, 2026
NEUTRAL
S-3/A
5/10
{
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 313.6% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 1174.9% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 1488.8% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.2B | 395.7% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.